Report cover image

Cell Therapy And Gene Therapy Markets

Publisher Kalorama Information
Published Feb 01, 2022
Length 291 Pages
SKU # KLI17152120

Description

Cell Therapy And Gene Therapy Markets

Cell and Gene Therapy World Market and Market Potential 22-021

Authoritative Information on Cell and Gene Therapy Markets

Cell and Gene Therapy World Market and Market Potential from Kalorama Information presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:
  • Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
  • Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
  • Cell and Gene Therapy Market Summary for United States by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
  • U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)
Scope

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.

The following conditions/disorders are covered:
  • Dermatology, including:
  • Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Skin cells)
  • Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
  • Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Cardiovascular and Blood Disorders, including:
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
  • Oncology, including:
  • Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
  • Oncology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
  • Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, ROW)
  • Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Ophthalmic Conditions, including:
  • Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
  • Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, Other countries)
  • Musculoskeletal Conditions and Disorders, including:
  • Musculoskeletal Cell Therapy Market, Estimated 2021 and Projected 2026 and 2031 ($ millions)
  • Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
  • Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Other Conditions, including:
  • Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
  • Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)

Table of Contents

291 Pages
    • Overview
    • Scope and Methodology
    • Market Overview and Potential
    • Introduction
    • Cell and Gene Therapy: Characteristics
    • Staffing
    • Manufacturing Process for CAR-T
    • Cell and Gene Therapy Manufacturing Processes
    • Cost
    • Reimbursement
    • Logistics
    • Mergers and Acquisitions
    • Partnerships, Agreements and Collaborations
    • Financing and Funding Deals
    • Regulatory Developments
    • Development and Pipeline Overview
    • Development Progress
    • Development by Condition/Disorder
    • Global Participation in Cell and Gene Therapy Development
    • Phase III Development
    • End User
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Causes of Cancer Growth
    • Global Cancer Burden
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Overview
    • Market Outlook
    • Principal Products
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
    • Regional Market Summary
    • Competitor Summary
    • Market Influences
    • Cell and Gene Therapy and Viral Vector Shortages
    • Global Market Summary
    • Cell vs. Gene Therapy Markets
    • Regional Market Overview
    • United States
    • Europe/European Union
    • Other Countries
    • Competitor Ranking in Cell and Gene Therapy Markets
    • Leading Influencers
    • Advaxis, Inc. (Biosight Therapeutics)
    • AlloSource
    • Alnylam Pharmaceuticals, Inc.
    • Amgen
    • AnGes Inc.
    • Anterogen Co Ltd.
    • Atara Biotherapeutics
    • Athersys, Inc
    • BioCardia
    • Biogen, Inc.
    • BioMarin Pharmaceuticals
    • bluebird bio, Inc.
    • BrainStorm Cell Therapeutics
    • Bristol-Myers Squibb
    • Caladrius Biosciences
    • Candel Therapeutics
    • Castle Creek Biosciences
    • Celyad Oncology
    • Cook Myosite, Inc
    • Cytori Therapeutics, Inc
    • Dendreon Pharmaceuticals LLC
    • FerGene, Inc/Ferring Pharmaceuticals
    • Gamida Cell Ltd.
    • GenSight Biologics S.A.
    • Gilead Sciences, Inc.
    • Gradalis, Inc
    • Helixmith
    • Inovio Pharmaceuticals, Inc.
    • Kiadis Pharma B.V. (Sanofi)
    • Medeor Therapeutics
    • MEDIPOST Co, Ltd.
    • MeiraGTx
    • Merck & Co., Inc.
    • Mesoblast Ltd.
    • Neurotech Pharmaceuticals. Inc.
    • Northwest Biotherapeutics, Inc.
    • Novartis AG
    • NuVasive Biologics
    • Orchard Therapeutics
    • Organogenesis
    • Orthofix
    • Osiris Therapeutics, Inc.( part of Smith & Nephew)
    • Pharmicell
    • Pluristem Therapeutics, Inc.
    • Sangamo Therapeutics
    • Sanofi
    • Sotio a.s.
    • Spark Therapeutics
    • Tessa Therapeutics, Ltd.
    • uniQure N.V.
    • VBL Therapeutics (Vascular Biogenics Ltd.)
    • Vericel Corporation

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us